S&P 500   3,294.61 (+0.72%)
DOW   26,664.40 (+0.89%)
QQQ   268.16 (+0.89%)
AAPL   435.59 (+2.48%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.34 (-0.38%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.90 (+2.74%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.12 (+0.66%)
AMD   77.82 (+0.50%)
T   29.62 (+0.14%)
F   6.68 (+1.06%)
ACB   10.43 (+2.36%)
GILD   71.59 (+2.96%)
NFLX   498.62 (+1.99%)
DIS   116.34 (-0.51%)
BAC   24.99 (+0.44%)
BA   162.22 (+2.67%)
S&P 500   3,294.61 (+0.72%)
DOW   26,664.40 (+0.89%)
QQQ   268.16 (+0.89%)
AAPL   435.59 (+2.48%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.34 (-0.38%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.90 (+2.74%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.12 (+0.66%)
AMD   77.82 (+0.50%)
T   29.62 (+0.14%)
F   6.68 (+1.06%)
ACB   10.43 (+2.36%)
GILD   71.59 (+2.96%)
NFLX   498.62 (+1.99%)
DIS   116.34 (-0.51%)
BAC   24.99 (+0.44%)
BA   162.22 (+2.67%)
S&P 500   3,294.61 (+0.72%)
DOW   26,664.40 (+0.89%)
QQQ   268.16 (+0.89%)
AAPL   435.59 (+2.48%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.34 (-0.38%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.90 (+2.74%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.12 (+0.66%)
AMD   77.82 (+0.50%)
T   29.62 (+0.14%)
F   6.68 (+1.06%)
ACB   10.43 (+2.36%)
GILD   71.59 (+2.96%)
NFLX   498.62 (+1.99%)
DIS   116.34 (-0.51%)
BAC   24.99 (+0.44%)
BA   162.22 (+2.67%)
S&P 500   3,294.61 (+0.72%)
DOW   26,664.40 (+0.89%)
QQQ   268.16 (+0.89%)
AAPL   435.59 (+2.48%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.34 (-0.38%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.90 (+2.74%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.12 (+0.66%)
AMD   77.82 (+0.50%)
T   29.62 (+0.14%)
F   6.68 (+1.06%)
ACB   10.43 (+2.36%)
GILD   71.59 (+2.96%)
NFLX   498.62 (+1.99%)
DIS   116.34 (-0.51%)
BAC   24.99 (+0.44%)
BA   162.22 (+2.67%)
Log in

NASDAQ:CEMIChembio Diagnostics Stock Price, Forecast & News

$5.82
+0.29 (+5.24 %)
(As of 08/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$5.45
Now: $5.82▼
$6.26
50-Day Range
$3.18
MA: $4.89▼
$10.45
52-Week Range
$2.25
Now: $5.82▼
$15.89
Volume274,558 shs
Average Volume8.26 million shs
Market Capitalization$117.39 million
P/E RatioN/A
Dividend YieldN/A
Beta2.51
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue virus, chikungunya virus, ebola, lassa, marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. In addition, the company develops tests for a specific form of cancer, concussion, and bovine tuberculosis; and handheld optical analyzers for rapid diagnostic tests. It sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC to develop a POC diagnostic test for traumatic brain injury; Foundation for Innovative New Diagnostics to develop a POC fever panel assay for life-threatening acute febrile illnesses; AstraZeneca to develop a POC test for eosinophilic respiratory disease; and LumiraDx to develop POC diagnostic tests for infectious diseases. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Medford, New York.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 3.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.23 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CEMI
Previous Symbol
CUSIPN/A
CIK1092662
Webwww.chembio.com
Phone631-924-1135

Debt

Debt-to-Equity Ratio1.36
Current Ratio3.48
Quick Ratio2.11

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$34.46 million
Price / Sales3.41
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.37 per share
Price / Book4.25

Profitability

EPS (Most Recent Fiscal Year)($0.79)
Net Income$-13,680,000.00
Net Margins-48.02%
Return on Equity-63.13%
Return on Assets-29.41%

Miscellaneous

Employees295
Outstanding Shares20,170,000
Market Cap$117.39 million
Next Earnings Date8/6/2020 (Confirmed)
OptionableNot Optionable
$5.82
+0.29 (+5.24 %)
(As of 08/3/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CEMI News and Ratings via Email

Sign-up to receive the latest news and ratings for CEMI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Chembio Diagnostics (NASDAQ:CEMI) Frequently Asked Questions

How has Chembio Diagnostics' stock been impacted by COVID-19 (Coronavirus)?

Chembio Diagnostics' stock was trading at $3.10 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CEMI stock has increased by 87.7% and is now trading at $5.82.
View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Chembio Diagnostics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chembio Diagnostics in the last year. There are currently 5 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Chembio Diagnostics.

When is Chembio Diagnostics' next earnings date?

Chembio Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020.
View our earnings forecast for Chembio Diagnostics.

How can I listen to Chembio Diagnostics' earnings call?

Chembio Diagnostics will be holding an earnings conference call on Thursday, August 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Chembio Diagnostics' earnings last quarter?

Chembio Diagnostics Inc (NASDAQ:CEMI) posted its quarterly earnings results on Monday, May, 4th. The company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by $0.02. The firm earned $6.86 million during the quarter. Chembio Diagnostics had a negative return on equity of 63.13% and a negative net margin of 48.02%.
View Chembio Diagnostics' earnings history.

What guidance has Chembio Diagnostics issued on next quarter's earnings?

Chembio Diagnostics issued an update on its second quarter 2020 After-Hours earnings guidance on Monday, July, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $4.5-4.7 million, compared to the consensus revenue estimate of $11.98 million.

What price target have analysts set for CEMI?

5 brokers have issued 12-month target prices for Chembio Diagnostics' stock. Their forecasts range from $4.00 to $8.00. On average, they expect Chembio Diagnostics' share price to reach $6.50 in the next twelve months. This suggests a possible upside of 11.7% from the stock's current price.
View analysts' price targets for Chembio Diagnostics.

Has Chembio Diagnostics been receiving favorable news coverage?

Media stories about CEMI stock have trended somewhat positive recently, InfoTrie reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Chembio Diagnostics earned a coverage optimism score of 1.6 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days.
View the latest news about Chembio Diagnostics.

Who are some of Chembio Diagnostics' key competitors?

Some companies that are related to Chembio Diagnostics include BioDelivery Sciences International (BDSI), Clovis Oncology (CLVS), Ocular Therapeutix (OCUL), XBiotech (XBIT), Catalyst Pharmaceuticals (CPRX), Albireo Pharma (ALBO), Avid Bioservices (CDMO), BELLUS Health (BLUSF), Puma Biotechnology (PBYI), Zafgen (ZFGN), Satsuma Pharmaceuticals (STSA), Rigel Pharmaceuticals (RIGL), Avedro (AVDR), Merus (MRUS) and 89bio (ETNB).
View all competitors.

What other stocks do shareholders of Chembio Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Chembio Diagnostics investors own include Prospect Capital (PSEC), Calumet Specialty Products Partners, L.P (CLMT), Two Harbors Investment (TWO), Blackrock Capital Investment (BKCC), Novocure (NVCR), Viper Energy Partners (VNOM), Summit Midstream Partners (SMLP), Washington Prime Group (WPG), Roper Technologies (ROP) and Rewalk Robotics (RWLK).

Who are Chembio Diagnostics' key executives?

Chembio Diagnostics' management team includes the following people:
  • Mr. John J. Sperzel III, Pres, CEO & Director (Age 55)
  • Mr. Neil A. Goldman, Exec. VP & CFO (Age 51)
  • Mr. Javan Esfandiari, Chief Science & Technology Officer and Exec. VP (Age 52)
  • Dr. Robert Passas Ph.D., Sr. VP & Chief Commercial Officer (Age 65)
  • Mr. David A. Gyorke, Sr. VP & COO (Age 59)

What is Chembio Diagnostics' stock symbol?

Chembio Diagnostics trades on the NASDAQ under the ticker symbol "CEMI."

Who are Chembio Diagnostics' major shareholders?

Chembio Diagnostics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Penbrook Management LLC (1.10%), Mackay Shields LLC (0.33%), Wedbush Securities Inc. (0.16%), Hancock Whitney Corp (0.07%), Avestar Capital LLC (0.06%) and UBS Group AG (0.04%). Company insiders that own Chembio Diagnostics stock include Javan Esfandiari, John Gary Potthoff and Robert Passas.
View institutional ownership trends for Chembio Diagnostics.

Which major investors are selling Chembio Diagnostics stock?

CEMI stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG.
View insider buying and selling activity for Chembio Diagnostics.

Which major investors are buying Chembio Diagnostics stock?

CEMI stock was purchased by a variety of institutional investors in the last quarter, including Mackay Shields LLC, Wedbush Securities Inc., Penbrook Management LLC, Hancock Whitney Corp, and Avestar Capital LLC. Company insiders that have bought Chembio Diagnostics stock in the last two years include John Gary Potthoff, and Robert Passas.
View insider buying and selling activity for Chembio Diagnostics.

How do I buy shares of Chembio Diagnostics?

Shares of CEMI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Chembio Diagnostics' stock price today?

One share of CEMI stock can currently be purchased for approximately $5.82.

How big of a company is Chembio Diagnostics?

Chembio Diagnostics has a market capitalization of $117.39 million and generates $34.46 million in revenue each year. The company earns $-13,680,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Chembio Diagnostics employs 295 workers across the globe.

What is Chembio Diagnostics' official website?

The official website for Chembio Diagnostics is www.chembio.com.

How can I contact Chembio Diagnostics?

Chembio Diagnostics' mailing address is 555 WIRELESS BLVD., HAUPPAUGE NY, 11788. The company can be reached via phone at 631-924-1135 or via email at [email protected]

This page was last updated on 8/3/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.